Cardiovascular Diagnostic Aptamer Development Services

The aptamers obtained through the screening of nucleic acid libraries have a strong affinity for target molecules and are recognized as a promising diagnostic reagent. Ace Therapeutics uses SELEX technology to screen aptamers from a library of random single-stranded nucleic acid sequences with high affinity for the target substance specifically to assist our customers in diagnostic development.

Aptamers in the Diagnostic of Cardiovascular Diseases

Aptamers are single-stranded oligonucleotides that allow them to be comparable to antibodies used in cardiac applications by forming unique structure-specific recognition and binding to targets in vivo. Based on the ability of single-stranded oligonucleotides to bind to specific target molecules, the concept of aptamers has gradually been known and applied to the development of diagnostic reagents. Chemically synthesized aptamers can be easily modified in a site-specific manner, and as a result they are widely used in the diagnostics of cardiovascular disease.

Fig. 1 Principle of sandwich aptamer-based LFA for the detection of thrombin. (Majdinasab M, et al., 2022)

In the current field of in vitro diagnostics, aptamers have shown great promise as possible alternatives to antibodies. Ace Therapeutics offers a wide range of unique aptamer screening and aptamer diagnostic reagent development services for in vitro diagnostics in the field of cardiovascular disease.

Aptamer Screening and Development Services

With many years of experience in aptamer research, we can provide aptamer screening as well as a full range of post-screening aptamer optimization services to advance the development of diagnostic methods for cardiovascular diseases.

Different Types of Aptamers

Our Aptamer Screening Process

Our Aptamer screening process can be specifically referenced as shown in the following flowchart.

Ace Therapeutics is a leading developer of in vitro diagnostic reagents for cardiovascular disease and aims to provide customers with comprehensive solutions for the development of novel aptamer diagnostic reagents. If you are interested in our services, please don't hesitate to contact us.

1. Majdinasab, M.; et al. Aptamer-based lateral flow assays: current trends in clinical diagnostic rapid tests. Pharmaceuticals (Basel). 2022, 15(1): 90.